Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No. Application No. 14503-0004US1 10/567,265

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant Norbert Zander et al.

(37 CFR §1.98(b))

Filing Date Group Art Unit April 10, 2008 1618

U.S. Patent Documents Desig. Examiner Document Publication Filing Date Initial ID` Number Date Patentee Class Subclass If Appropriate 4.001.200 01/04/77 Bonsen et al. 1 2 4 001 401 01/04/77 Bonsen et al 3 4.053,590 10/11/77 Bonsen et al. 4.061.736 Bonsen et al. 4 12/06/77 5 4 925 677 05/15/90 Feijen 6 5,079,337 01/07/92 Leonard et al. 5.723.589 03/03/98 Milikovic et al. 7 8 5.880.270 03/09/99 Berninger et al. 9 5,952,347 09/14/99 Arison et al. 01/04/00 10 6.011.008 Domb et al. 11 6,261,800 07/17/01 Nikolics et al. 12 6,340,746 01/22/02 Roberts et al 13 6.375.846 04/23/02 Jarrett et al. 6,875,594 14 04/05/05 Muir et al 15 7.115.576 10/03/06 Sommermever 02/20/07 16 7.179.617 DeFrees et al. 7,285,661 10/23/07 17 Sommermever et al. 18 2004/0043446 03/04/04 DeFrees et al. 2002/0151006 10/17/02 Muir et al.

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Desig. Document		Document	Publication	Publication Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	20	0 127 839	07/15/92	EP				
	21	0 218 825	04/22/87	EP				
	22	0 331 471	12/16/92	EP				
	23	0 342 557	11/23/94	EP				
	24	0 549 721	04/13/94	EP				

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application No. Substitute Form PTO-1449 U.S. Department of Commerce Attorney Docket No. (Modified) Patent and Trademark Office 10/567,265 14503-0004US1 Applicant Information Disclosure Statement Norbert Zander et al. by Applicant (Use several sheets if necessary) Filing Date Group Art Unit April 10, 2008 1618 (37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications									
Examiner	Desig.	Document	Publication	Country or				Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
	25	1 064 951	01/03/01	EP					
	26	1 424 086	06/02/04	EP					
_	27	1 549 246	10/19/76	GB					
	28	WO 80/02374	11/13/80	WO					
	29	WO 94/07536	04/14/94	WO					
	30	WO 00/78355	12/28/00	WO					
	31	WO 01/70272	09/27/01	WO					
	32	WO 02/20033	03/14/02	WO					
	33	WO 03/31464	04/17/03	WO					
	34	WO 03/31581	04/17/03	WO					
	35	WO 03/70772	08/28/03	WO			Abst.		
	36	WO 04/24776	03/25/04	wo					
	37	WO 04/24777	03/25/04	WO					
	38	WO 04/30701	04/15/04	WO					
	39	WO 04/33651	04/22/04	WO					
	40	WO 05/14024	02/17/05	wo					
	41	WO 05/14035	02/17/05	wo					
	42	WO 05/14050	02/17/05	WO					
	43	WO 05/14655	02/17/05	wo					
	44	WO 05/74993	08/18/05	wo					
	45	WO 05/92390	10/06/05	wo					
	46	WO 06/108052	10/12/06	WO					

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Desig.						
Initial ID Document						
47 Adamczyk and Fishpaugh, "A Solid Supported Synthesis of Thiol Esters," <u>Tetra</u> 37(25):4305-4308		Adamczyk and Fishpaugh, "A Solid Supported Synthesis of Thiol Esters," <u>Tetrahedron Lett.</u> , 1996, 37(25):4305-4308				
Aly et al., "Hemophilia A due to mutations that create new N-glycosylation sites," Proc. Natl. Sci. USA, 1992, 89(11):4933-4937						

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

			511441 <u>5</u> 01 <u>0</u>
Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
	losure Statement plicant	Applicant Norbert Zander et al.	
(Use several sh	eets if necessary)	Filing Date April 10, 2008	Group Art Unit 1618

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	49	Anderson and Meister, "Inhibition of γ -glutamyl transpeptidase and induction of glutathionuria by γ -			
		glutamyl amino acids," Proc. Natl. Acad. Sci. USA, 1986, 83:5029-5032			
		Andersson et al., "Isolation and characterization of human factor VIII: molecular forms in			
	50	commercial factor VIII concentrate, cryoprecipitate, and plasma," Proc. Natl. Acad. Sci. USA, 1986,			
		83(9):2979-2983 Armitage, "Emerging applications of recombinant human granulocyte-macrophage colony-			
	51	stimulating factor," Blood, 1998, 92(12):4491-4508			
		Axèn et al., "Chemical Coupling of Peptides and Proteins to Polysaccharides by Means of Cyanogen			
	52	Halides," Nature, 1967, 214:1302-1304			
		Balland et al., "Characterisation of two differently processed forms of human recombinant factor IX			
	53	synthesised in CHO cells transformed with a polycistronic vector," Eur. J. Biochem., 1988,			
		172(3):565-572			
		Bauer and Rosenberg, "Role of antithrombin III as a regulator of in vivo coagulation," Semin.			
	54	Hematol., 1991, 28(1):10-18			
	55	Berg et al., "Engineering the proteolytic specificity of activated protein C improves its			
	33	pharmacological properties," Proc. Natl. Acad. Sci. USA, 2003, 100(8):4423-4428			
	56	Bhattacharyya et al., "Recombinant Factor VIII for Haemophilia," CRIPS, 2003, 4(3):2-8			
		Bjork and Danielsson, "Antithrombin and related inhibitors of coagulation proteinases," Proteinase			
	57	Inhibitors, Barrett and Salvesen (eds.), 1986, Chapter 17, Amsterdam, The Netherlands, Elsevier			
		Science Publishers (Biomedical Division), pp. 489-513			
	58	Boorsma et al., "Bioprocess applications of a Sindbis virus-based temperature-inducible expression			
	•••	system," <u>Biotechnol. Bioeng.</u> , 2002, 79(6): 602-609			
	59	Carrell et al., "Human alpha 1-antitrypsin: carbohydrate attachment and sequence homology," FEBS Letters, 1981, 135(2):301-303			
		Carrell et al., "Structural mobility of antithrombin and its modulation by heparin," Thromb.			
	60	Haemost., 1997, 78(1):516-519			
	61	Carver et al., "Expression of human alpha 1 antitrypsin in transgenic sheep," Cytotechnology, 1992,			
	01	9(1-3):77-84			
		Castillo et al., "Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of			
	62	the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases,"			
		Anal. Biochem., 1979, 99(1):53-64			
		Cebon et al., "Granulocyte-macrophage colony stimulating factor from human lymphocytes. The			
	63	effect of glycosylation on receptor binding and biological activity," J. Biol. Chem., 1990,			
		265(8):4483-4491			
	64	Cera et al., "Water-soluble polysaccharide-anthracycline conjugates: biological activity," Anti-			
		Cancer Drug Design, 1992, 7(2):143-151 Cervigni et al., "Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation,"			
	65	Angewandte Chemie International Edition in English, 1996, 35(11):1230-1232			
	66	Chan et al., "Preparation of O-esters from the corresponding thiol esters: tert-butyl			
	00	cyclohexanecarboxylate," Organic Syntheses Coll., 1990, 7:87-93			
		Chaplin and Kennedy (eds.), Carbohydrate Analysis: a practical approach, 1994, 2nd Edition,			
	67	Chapter 1 "Monosaccharides" pp. 1-41, Chapter 2 "Oligosaccharides" pp. 42-72, Chapter 3 "Neutral			
		Polysaccharides" pp. 73-124, Chapter 5 "Glycoproteins" pp. 175-177 and 181-293, IRL Press			
Evernines Cian	oturo	Pote Considered			

Examiner Signature

Date Considered

EXAMINER: Initials citation considered Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
Information Disclosure Statement by Applicant		Applicant Norbert Zander et al.	
(Use several si	neets if necessary)	Filing Date April 10, 2008	Group Art Unit 1618

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document				
	68	Chen et al., "Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography," VoxSanguinis , 1998, 74(4):232-241				
	69	Choay et al., "Structural studies on a biologically active hexasaccharide obtained from heparin," Ann. NY Acad. Sci., 1981, 370:644-649				
	70	Choay et al., "Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity," <u>Biochem. Biophys. Res.</u> <u>Commun.</u> , 1983, 116(2):492-499				
	71	Colman, "Production of therapeutic proteins in the milk of transgenic livestock," <u>Biochem. Soc. Symp.</u> , 1998, 63:141-147				
	72	Conradt et al., "Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked earbohydrate chains and their location within the polypeptide," J. Biol. Chem., 1989, 264:17368-17373				
	73	Corey and Clark, "A New Method for the Synthesis of 2-Pyridinethiol Carboxylic Esters," <u>Tetrahedron Lett.</u> , 1979, 2875-2878				
	74	De Koning et al., "An approach to the synthesis of peptide-PNA-peptide conjugates via native ligation," Tetrahedron Letters, 2002, 43(45):8173-8176				
	75	Denzlinger et al., "Differential activation of the endogenous leukotriene biosynthesis by two different preparations of Granulocyte-Macrophage Colony-Stimulating Factor in healthy volunteers," <u>Blood</u> , 1993, 81(8):2007-2013				
	76	Dictionary of Chemistry and Chemical Technology, 2003, page 769 (English translation provided)				
	77	Dieterich et al., "Hydroxyethyl Starch Antibodies in Humans: Incidence and Clinical Relevance," <u>Anesth. Analg.</u> , 1998, 86:1123-1126				
	78	Donahue et al., "Effects of N-linked carbohydrates on the in vivo properties of human GM-CSF," Cold Spring Harbor Symp. Quant. Biol., 1986, 51:685-692				
	79	Franzen et al., "Structural studies on the carbohydrate portion of human antithrombin III," <u>J. Biol.</u> <a <u="" bonds="" disulfide="" folliele-stimulating="" hormone,"="" href="https://dx.doi.org/10.100/j.nc/10.100/</td></tr><tr><td></td><td>80</td><td>Fujiki et al., " human="" in="" on="" pituitary="" studies="" the="">Biochim. Biophys. Acta, 1980, 624:428-435				
	81	Goldstein and Gelb, "An alternate preparation of thioester resin linkers for solid-phase synthesis of peptide C-terminal thioacids," Tetrahedron Lett., 2000, 41(16):2797-2800				
	82	Goronzy et al., "T-Cell Derived Lymphokines as Regulators of Chronic Inflammation: Potential Targets for Immunomodulation," Am. J. Therap., 1996, 3(2):109-114				
	83	Gribben et al., "Development of antibodies to unprotected glycosylation sites on recombinant GM-CSF," Lancet, 1990, 335:434-437				
	84	Harris et al., "Pegylation. A novel process for modifying pharmacokinetics," Clin. Pharmacokinet., 2001, 40(7):539-551				
	85	He et al., "A simplified system for generating recombinant adenoviruses," Proc. Natl. Acad. Sci. USA , 1998, 95(5):2509-2514				
	86	Hodges and Chan, "Locations of oligosaccharide chains in human alpha 1-protease inhibitor and oligosaccharide structures at each site," <u>Biochemistry</u> , 1982, 21(11):2805-2810				
	87	Hodges et al., "Structure of the oligosaccharide chains in human alpha 1-protease inhibitor," <u>J. Biol. Chem.</u> , 1979, 254(17):8208-8212				

I	Examiner Signature	Date Considered
ı		
ı		
ı	EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
ı	next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
Information Disclosure Statement by Applicant		Applicant Norbert Zander et al.	
(Use several she	ets if necessary)	Filing Date	Group Art Unit
(37 CFR §1.98(b))		April 10, 2008	1618

0	ther D	ocuments (include Author, Title, Date, and Place of Publication)
	Desig.	
Initial	ID	Document
	88	Hovgaard et al., "Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF," <u>Eur. J. Clin. Inv.</u> , 1992, 22:45-49
		Hovinen et al., "Ethyl[2-deoxy-5-0-(4,4'-dimethoxytrityt)-α-and β-D-erythro-pentofuranosyl]
	89	acctates as versatile intermediates in nucleic acid chemistry," <u>Nucleosides Nucleotides</u> , 1999, 18:1263-1264
	90	Iakovenko et al., "Semi-synthetic Rab proteins as tools for studying intermolecular interactions," FEBS Letters, 2000, 468:155-158
	91	Ingenito et al., "Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry," J. Am. Chem. Soc., 1999, 121:11369-11374
	92	Jaques et al., "N.M.R. spectroscopy and calcium binding of sialic acids: N-glycolylneuraminic acid and periodate-oxidized N-acetylneuraminic acid," Carb. Res., 1980, 83:21-32
	93	Karpusas et al., "Commercial preparations of interferon beta are Betaseron (IFN beta 1b), Avonex and Rebif (IFN beta 1a)," Proc. Natl. Acad. Sci. USA, 1997, 94:11813-11818
	94	Kaufman et al., "Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells," J. Biol. Chem., 1988, 263(13):6352-6362
	95	Kaushansky et al., "Role of carbohydrate in the function of human Granulocyte-Macrophage Colony-Stimulating Factor," Biochemistry, 1987, 26:4861-4867
	96	Keene et al., "Expression of biologically active human follitropin in Chinese hamster ovary cells," J. Biol. Chem., 1989, 264;4769-4775
	97	Kochendoerfer et al., "Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein," Science, 2003, 299(5608):884-887
	98	Kraehenbuhl et al., "Preparation and Characterization of an Immuno Electron Microscope Tracer consisting of a Heme Octa Peptide coupled to FAB," J. Exp. Med., 1974, 139(1):208-223
99		Lahiri et al., "Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein," <u>Arch. Biochem.</u> <u>Biophys.</u> , 1976, 175:737-747
	100	Lapthorn et al., "Crystal structure of human chorionic gonadotropin," Nature, 1994, 369:455-461
	101	Lee et al., "Conjugation of Trypsin by Temperature-Sensitive Polymers Containing a Carbohydrate Moiety: Thermal Modulation of Enzyme Activity," <u>Biotechnol. Prog.</u> , 1998, 14:508-516
	102	Li et al., "Direct preparation of peptide thioesters using an Fmoc solid-phase method," Tetrahedron Lett., 1998, 39(47):8669-8672
	103	Lin et al., "L-Cysteine as a water-soluble cation scavenger in the removal of the 2,4,6-trimethoxybenzyl group from thiols," Tetrahedron Lett., 2002, 43:4531-4533
	104	Luo et al., "Controlled DNA delivery systems," Pharm. Res., 1999, 16(8):1300-1308
	105	March, Advanced Organic Chemistry, 1992, 4th edition, John Wiley and Sons, New York, p.409
	106	Masamune et al., "A General, Selective Synthesis of Thiol Esters," Can. J. Chem., 1975, 53:3693-3695
	107	Masamune et al., "Tylonolide hemiacetal, the aglycone of tylosin, and its partial synthesis," <u>J. Am. Chem. Soc.</u> , 1976, 98(24):7874-7875
	108	Masuda et al., "Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir," <u>Bioorg. Med. Chem. Lett.</u> , 2003, 13(4):669-673
	109	Mega et al., "Studies on the oligosaccharide chains of human alpha 1-protease inhibitor. I. Isolation of glycopeptides," J. Biol. Chem., 1980, 255(9):4053-4056
Examiner Signat	ure	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			D11441
Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
Information Disclo		Applicant Norbert Zander et al.	
(Use several shee (37 CFR §1.98(b))	ts if necessary)	Filing Date April 10, 2008	Group Art Unit 1618

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Desig.			
Initial	ID	Document	
	110	Mega et al., "Studies on the Oligosaccharide Chains of Human α1-Protease Inhibitor. II. Structure of oligosaccharides," J. Bjol. Chem., 1980, 255(9):4057-4061	
	111	Menache, "Antithrombin III: introduction," Semin. Hematol., 1991, 28(1):1-2	
	112	Menache et al., "Antithrombin III: physiology, deficiency, and replacement therapy," <u>Transfusion</u> , 1992, 32(6):580-588	
	113	Merck Index 2006, Definition of Dimethyl Sulfoxide, Merck & Co., 14th Edition, accessed online: http://themerckindex.cambridgesoft.com/themerckindex/index.asp on Sept. 4, 2007	
	114	Ming et al., "Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium," J. Mol. Cell. Immunol., 1989, 4:203-211	
	115	Moonen et al., "Increased biological activity of deglycosylated recombinant human granulocyte- macrophage colony-stimulating factor produced by yeast or animal cells," <u>Proc. Natl. Acad. Sci.</u> USA, 1987, 84(13):4428-4431	
	116	Mori et al., "The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator," J. Biol. Chem., 1995, 270(7):3261-3267	
	117	Mueller et al., "Recombinant Glycoprotein Product Quality in Proliferation-Controlled BHK-21 Cells," Biotechnol. Bioeng., 1999, 65(5):529-536	
	118	Muir et al., "Expressed protein ligation: a general method for protein engineering," Proc. Natl. Acad. Sci. USA , 1998, 95(12):6705-6710	
	119	Mukaiyama et al., "Peptide Synthesis via Oxidation-Reduction Condensation by the Use of Non- metallic Compound as a Mercaptan Scavenger," Bull. Chem. Soc. Jpn., 1970, 43:1271	
	120	Mumberg et al., "Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression," Nucl. Acids Res., 1994, 22(25):5767-5768	
	121	Murano et al., "Some properties of antithrombin-III and its concentration in human plasma," Thromb. Res., 1980, 18(1-2):259-262	
	122	Ohta et al., "Usefulness of Glycopeptide Mapping by Liquid Chromatography/Mass Spectrometry in Comparability Assessment of Glycoprotein Products," <u>Biologicals</u> , 2002, 30(3):235-244	
	123	Okamoto et al., "Purification and characterization of three forms of differently glycosylated recombinant human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Arch. Biochem. Biophys.</u> , 1991, 286(2):562-568	
	124	Olson and Bjork, "Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects," <u>J</u> <u>Biol.</u> Chem., 1991, 266(10):6353-6364	
	125	Olson et al., "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement," J. Biol. Chem., 1992, 267(18):12528-12538	
	126	Opal et al., "Antithrombin, heparin, and heparan sulfate," Crit. Care Med., 2002, 30(5):S325-S331	
	127	Pelter et al., "Synthesis of Thioesters by Reactions of Carboxylic Acids with Tris-(ethylthio)borane," J. Am. Chem. Soc., Perkin Trans I, 1977, 1672-674	
	128	Peterson, The Physiological Inhibitions of Blood Coagulation and Fibrinolysis, Elsevier/ North- Holland Biomedical Press 1979, p. 43	
	129	Pike et al., "Heparin-dependent Modification of the Reactive Center Arginine of Antithrombin and Consequent Increase in Heparin Binding Affinity," J. Biol. Chem., 1997, 272(32):19652-19655	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
	sclosure Statement pplicant	Applicant Norbert Zander et al.	
(Use several sheets if necessary)		Filing Date	Group Art Unit
(37 CFR §1.98(b))		April 10, 2008	1618

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner			
Initial	ID	Document Ragnhammar et al., "Induction of anti-recombinant human Granulocyte-Macrophage	
	130	Colony-Stimulating Factor (Escherichia coli-derived) antibodies and clinical effects in	
	130	nonimmunocompromised patients," Blood, 1994, 84:4078-4087	
		Rapoport et al., "Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner	
	131	membranes," Annu. Rev. Biochem., 1996, 65:271-303	
	132	Reddy et al., "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C,"	
	132	Advanced Drug Delivery Reviews, 2002, 54:571-586	
	133	Revoltella et al., "Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum," Leukemia and Lymphoma, 1997, 26:29-34	
	134	Roemisch et al., "Antithrombin: a new look at the actions of a serine protease inhibitor," Blood	
	151	Coagul Fibrinolysism, 2002, 13(8):657-670	
	135	Römpp Chemielexikon, Thieme Verlag Stuttgart, Germany, 9th edition, 1990, Volume 9, pages 2281-2285	
	136	Rosenberg, "Role of heparin and heparinlike molecules in thrombosis and atherosclerosis," Fed. Proc., 1985, 44:404-409	
	137	Rosenberg et al., "Antithrombin-III," Rev. Hematol., 1986, 2:351-416	
	138	Schlesinger, "Alphavirusesvectors for the expression of heterologous genes," <u>Trends Biotechnol.</u> , 1993, 11(1):18-22	
	120	Shin et al., "Fmoc-Based Synthesis of Peptide-a Thioesters: Application to the Total Chemical	
	139	Synthesis of a Glycoprotein by Native Chemical Ligation," <u>J. Am. Chem. Soc.</u> , 1999, 121:11684- 11689	
	140	Somogyi, "Determination of reducing sugars," Meth. Carb. Chem., 1962, 1:384-386	
	141	Spellman et al., "Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells," J. Biol. Chem., 1989, 264:14100-14111	
	142	Stetsenko et al., "Efficient conjugation of peptides to oligonucleotides by native ligation," J. Org. Chem., 2000, 65(16):4900-4908	
		Stewart et.al., "Identification of the mechanism responsible for the increased fibrin specificity of	
	143	TNK-tissue plasminogen activator relative to tissue plasminogen activator," <u>J. Biol. Chem.</u> , 2000, 275(14):10112-10120	
	144	Tebbutt, "Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics," Curr. Opin. Mol. Ther., 2000, 2(2):199-204	
	145	Thim et al., "Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells," Biochemistry, 1988, 27:7785-7793	
	146	Toole et al., "Molecular cloning of a cDNA encoding human antihaemophilic factor," Nature, 1984, 312(5992):342-347	
	147	Travis and Salvesen, "Human plasma proteinase inhibitors," Ann. Rev. Biochem., 1983, 52:655-709	
		Ubeda and Habener, "The large subunit of the DNA replication complex C (DSEB/RF-C140)	
	148	cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis," J. Biol. Chem., 1997, 272(31):19562-19568	
		Veronese, "Peptide and protein PEGylation; a review of problems and solutions," Biomaterials,	
	149	2001, 22(5):405-417	

ı	Examiner Signature	Date Considered		
ı				
ı				
ı				
ı	EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with			
next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
	closure Statement oplicant	Applicant Norbert Zander et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 10, 2008	Group Art Unit 1618

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.		
Initial	ID	Document	
Wadhwa et al., "Immunogenicity of Granulocyte-Macrophage Colony-Stimulating Factor (G		Wadhwa et al., "Immunogenicity of Granulocyte-Macrophage Colony-Stimulating Factor (GM-	
	150	CSF) products in patients undergoing combination therapy with GM-CSF," Clinical Cancer	
Research, 1999, 5:1351-1361		Research, 1999, 5:1351-1361	
Wasley et al., "The Importance of N- and O-Linked Oligosaccharides for the Biosynthesis Vitro and In Vivo Biologic Activities of Erythropoietin," Blood, 1991, 77(12):2624-2632		Wasley et al., "The Importance of N- and O-Linked Oligosaccharides for the Biosynthesis and In	
		Vitro and In Vivo Biologic Activities of Erythropoietin," Blood, 1991, 77(12):2624-2632	
Watanabe et al., "A facile synthesis of carboxylic thiol esters from carboxylic ac Chem. Lett., 1976, 741-742		Watanabe et al., "A facile synthesis of carboxylic thiol esters from carboxylic acids and thiols,"	
		Chem. Lett., 1976, 741-742	
Weisshaar et al., "NMR investigations of the N-linked oligosaccharide sites of human lutropin," Eur. J. Biochem., 1991, 195:257-268		Weisshaar et al., "NMR investigations of the N-linked oligosaccharides at individual glycosylation	
		sites of human lutropin," Eur. J. Biochem., 1991, 195:257-268	
Wright et al., "High level expression of active human alpha-1-antitrypsin in the milk of sheep," Biotechnology NY, 1991, 9:830-834		Wright et al., "High level expression of active human alpha-1-antitrypsin in the milk of transgenic	
		sheep," Biotechnology NY, 1991, 9:830-834	
Yoshitake et al., "Nucleotide sequence of the gene for human factor IX (antihemophilic fa Biochemistry, 1985, 24:3736-3750		Yoshitake et al., "Nucleotide sequence of the gene for human factor IX (antihemophilic factor B),"	
		Biochemistry, 1985, 24:3736-3750	

	Examiner Signature	Date Considered	
	Examinor digitators	Date Gonsidered	
	EVALUATION IN THE PROPERTY OF	Constitution of the Consti	
	EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with		
	next communication to applicant.		
- 1	now communication to approant		